Long-term clinical course of acute pulmonary embolism

Blood Reviews

Volumn 27, Issue 4, 2013, Pages 185-192

  den Exter, P L ^a   van der Hulle, T ^a   Lankeit, M ^b   Huisman, M V ^a   Klok, F A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Arterial cardiovascular events; Aspirin; CTEPH; DOAC; Mortality; Recurrent pulmonary embolism; Statin; Vitamin K antagonists

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHENPROCOUMON; PLACEBO; RIVAROXABAN; WARFARIN;

ADVERSE OUTCOME; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; MORTALITY; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RISK BENEFIT ANALYSIS; SCORING SYSTEM; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ARTERIAL CARDIOVASCULAR EVENTS; ASPIRIN; CTEPH; DOAC; MORTALITY; RECURRENT PULMONARY EMBOLISM; STATIN; VITAMIN K ANTAGONISTS;

ACUTE DISEASE; ANTICOAGULANTS; HUMANS; PROGNOSIS; PULMONARY EMBOLISM; RISK FACTORS;

EID: 84881376823     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2013.06.003     Document Type: Article

References (75)

1. Kearon C., Akl E.A., Comerota A.J., Prandoni P., Bounameaux H., Goldhaber S.Z., et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e419S-e494S.
2. Torbicki A., Perrier A., Konstantinides S., Agnelli G., Galiè N., Pruszczyk P., et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008, 29:2276-2315.
3. Klok F.A., Zondag W., van Kralingen K.W., van Dijk A.P., Tamsma J.T., Heyning F.H., et al. Patient outcomes after acute pulmonary embolism. A pooled survival analysis of different adverse events. Am J Respir Crit Care Med 2010, 181:501-506.
4. Baglin T., Douketis J., Tosetto A., Marcucci M., Cushman M., Kyrle P., et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost 2010, 8:2436-2442.
5. Fedullo P., Kerr K.M., Kim N.H., Auger W.R. Chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2011, 183:1605-1613.
6. Becattini C., Vedovati M.C., Ageno W., Dentali F., Agnelli G. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. J Thromb Haemost 2010, 8:891-897.
7. Flinterman L.E., van Hylckama Vlieg A., Cannegieter S.C., Rosendaal F.R. Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med 2012, 9:e1001155.
8. Klok F.A., van Kralingen K.W., van Dijk A.P., Heyning F.H., Vliegen H.W., Huisman M.V. Prevalence and potential determinants of exertional dyspnea after acute pulmonary embolism. Respir Med 2010, 104:1744-1749.
9. Klok F.A., van Kralingen K.W., van Dijk A.P., Heyning F.H., Vliegen H.W., Kaptein A.A., et al. Quality of life in long-term survivors of acute pulmonary embolism. Chest 2010, 138:1432-1440.
10. Heit J.A., Mohr D.N., Silverstein M.D., Petterson T.M., O'Fallon W.M., Melton L.J. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000, 160:761-768.
11. Kyrle P.A., Rosendaal F.R., Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet 2010;376:2032-9. Am J Respir Crit Care Med 2010, 181:501-506.
12. Prandoni P., Noventa F., Ghirarduzzi A., Pengo V., Bernardi E., Pesavento R., et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1626 patients. Haematologica 2007, 91:199-205.
13. Hansson P.O., Sörbo J., Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000, 160:769-774.
14. Kyrle P.A., Minar E., Bialonczyk C., Hirschl M., Weltermann A., Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004, 350:2558-2563.
15. Eichinger S., Heinze G., Jandeck L.M., Kyrle P.A. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010, 121:1630-1636.
16. Rodger M.A., Kahn S.R., Wells P.S., Anderson D.A., Chagnon I., Le G.G., et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008, 179:417-426.
17. Tosetto A., Iorio A., Marcucci M., Baglin T., Cushman M., Eichinger S., et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012, 10:1019-1025.
18. Palareti G., Cosmi B., Legnani C., Tosetto A., Brusi C., Iorio A., et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006, 355:1780-1789.
19. Douketis J., Tosetto A., Marcucci M., Baglin T., Cushman M., Eichinger S., et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med 2010, 153:523-531.
20. Bruinstroop E., Klok F.A., Van De Ree M.A., Oosterwijk F.L., Huisman M.V. Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost 2009, 7:611-618.
21. Linkins L.A., Choi P.T., Douketis J.D. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003, 139:893-900.
22. Bonderman D., Wilkens H., Wakounig S., Schäfers H.J., Jansa P., Lindner J., et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009, 33:325-331.
23. Pepke-Zaba J., Delcroix M., Lang I., Mayer E., Jansa P., Ambroz D., et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011, 124:1973-1978.
24. Fedullo P.F., Auger W.R., Kerr K.M., Kim N.H. Chronic thromboembolic pulmonary hypertension. Semin Respir Crit Care Med 2003, 24:273-285.
25. Miniati M., Monti S., Bottai M., Scoscia E., Bauleo C., Tonelli L., et al. Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism. Medicine (Baltimore) 2006, 85:253-262.
26. Klok F.A., van Kralingen K.W., van Dijk A.P., Heyning F.H., Vliegen H.W., Huisman M.V. Prospective cardiopulmonary screening program to detect chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Haematologica 2010, 95:970-975.
27. Becattini C., Agnelli G., Pesavento R., Silingardi M., Poggio R., Taliani M.R., et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 2006, 130:172-175.
28. Dentali F., Donadini M., Gianni M., Bertolini A., Squizzato A., Venco A., et al. Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism. Thromb Res 2009, 124:256-258.
29. Pengo V., Lensing A.W., Prins M.H., Marchiori A., Davidson B.L., Tiozzo F., et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004, 350:2257-2264.
30. Poli D., Miniati M. The incidence of recurrent venous thromboembolism and chronic thromboembolic pulmonary hypertension following a first episode of pulmonary embolism. Curr Opin Pulm Med 2011, 17:392-397.
31. Surie S., Gibson N.S., Gerdes V.E., Bouma B.J., van Eck-Smit B.L., Buller H.R., et al. Active search for chronic thromboembolic pulmonary hypertension does not appear indicated after acute pulmonary embolism. Thromb Res 2010, 125:e202-e205.
32. Klok F.A., Surie S., Kempf T., Eikenboom J., van Straalen J.P., van Kralingen K.W., et al. A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Thromb Res 2011, 128:21-26.
33. Galiè N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barbera J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30:2493-2537.
34. Jenkins D.P., Madani M., Mayer E., Kerr K., Kim N., Klepetko W., et al. Surgical treatment of chronic thromboembolic pulmonary hypertension. Eur Respir J 2013, 41:735-742.
35. Lowe G.D. Common risk factors for both arterial and venous thrombosis. Br J Haematol 2008, 140:488-495.
36. Becattini C., Agnelli G., Prandoni P., Silingardi M., Salvi R., Taliani M.R., et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2005, 26:77-83.
37. Klok F.A., Mos I.C., Broek L., Tamsma J.T., Rosendaal F.R., de Roos A., et al. Risk of arterial cardiovascular events in patients after pulmonary embolism. Blood 2009, 114:1484-1488.
38. Brighton T.A., Eikelboom J.W., Mann K., Mister R., Gallus A., Ockelford P., et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012, 367:1979-1987.
39. Ageno W., Becattini C., Brighton T., Selby R., Kamphuisen P.W. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008, 117:93-102.
40. Ye Z., Liu E.H., Higgins J.P., Keavney B.D., Lowe G.D., Collins R., et al. Seven haemostatic genepolymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006, 367:651-658.
41. Lijfering W.M., Flinterman L.E., Vandenbroucke J.P., Rosendaal F.R., Cannegieter S.C. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost 2011, 37:885-896.
42. Wood K.E. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002, 121:877-905.
43. Douketis J.D., Kearon C., Bates S., Duku E.K., Ginsberg J.S. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998, 279:458-462.
44. Naess I.A., Christiansen S.C., Romundstad P., Cannegieter S.C., Rosendaal F.R., Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007, 5:692-699.
45. Reitter S.E., Waldhoer T., Mayerhofer M., Eigenbauer E., Ay C., Kyrle P.A., et al. Long-term survival of patients with a history of venous thromboembolism. Ann Hematol 2011, 90:585-594.
46. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton L.J. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999, 159:445-453.
47. Schulman S., Lindmarker P., Holmström M., Lärfars G., Carlsson A., Nicol P., et al. Post-thrombotic syndrome, recurrence, and death 10years after the first episode of venous thromboembolism treated with warfarin for 6weeks or 6months. J Thromb Haemost 2006, 4:734-742.
48. Agnelli G., Prandoni P., Santamaria M.G., Bagatella P., Iorio A., Bazzan M., et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001, 345:165-169.
49. Kearon C., Gent M., Hirsh J., Weitz J., Kovacs M.J., Anderson D.R., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999, 340:901-907.
50. Ridker P.M., Goldhaber S.Z., Danielson E., Rosenberg Y., Eby C.S., Deitcher S.R., et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003, 348:1425-1434.
51. Ost D., Tepper J., Mihara H., Lander O., Heinzer R., Fein A. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA 2005, 294:706-715.
52. Agnelli G., Prandoni P., Becattini C., Silingardi M., Taliani M.R., Miccio M., et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003, 139:19-25.
53. Rodger M., Carrier M., Gandara E., Le G.G. Unprovoked venous thromboembolism: short term or indefinite anticoagulation? Balancing long-term risk and benefit. Blood Rev 2010, 24:171-178.
54. Carrier M., Le Gal G., Wells P.S., Rodger M.A. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010, 152:578-589.
55. Ageno W., Gallus A.S., Wittkowsky A., Crowther M., Hylek E.M., Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e44S-e88S.
56. Budnitz D.S., Lovegrove M.C., Shehab N., Richards C.L. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011, 365:2002-2012.
57. Heneghan C., Ward A., Perera R., Bankhead C., Fuller A., et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012, 379:322-334. Self-Monitoring Trialist Collaboration.
58. Carlquist J.F., Anderson J.L. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation 2011, 124:2554-2559.
59. Epstein R.S., Moyer T.P., Aubert R.E., O Kane D.J., Xia F., Verbrugge R.R., et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010, 55:2804-2812.
60. Anand S.S., Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999, 282:2058-2067.
61. Bauersachs R., Berkowitz S.D., Brenner B., Buller H.R., Decousus H., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510. EINSTEIN Investigators.
62. Schulman S., Kearon C., Kakkar A.K., Schellong S., Eriksson H., Baanstra D., et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013, 368:709-718.
63. Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M., et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013, 368:699-708.
64. Uchino K., Hernandez A.V. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012, 172:397-402.
65. Connolly S.J., Ezekowitz M.D., Yusuf S., Reilly P.A., Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med 2010, 363:1875-1876. Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators.
66. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' collaboration.
67. Derry S., Loke Y.K. Risk of gastrointestinal haemorrhage with long-term use of aspirin: meta-analysis. BMJ 2000, 321:1183-1187.
68. Seshasai S.R., Wijesuriya S., Sivakumaran R., Nethercott S., Erqou S., Sattar N., et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012, 172:209-216.
69. Becattini C., Agnelli G., Schenone A., Eichinger S., Bucherini E., Silingardi M., et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012, 366:1959-1967.
70. Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists' (CTT) Collaboration.
71. Undas A., Brummel-Ziedins K.E., Mann K.G. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005, 25:287-294.
72. Glynn R.J., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009, 360:1851-1861.
73. Squizzato A., Galli M., Romualdi E., Dentali F., Kamphuisen P.W., Guasti L., et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J 2010, 31:1248-1256.
74. Rahimi K., Bhala N., Kamphuisen P., Emberson J., Biere-Rafi S., Krane V., et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med 2012, 9:e1001310.
75. Biere-Rafi S., Hutten B.A., Squizzato A., Ageno W., Souverein P.C., de Boer A., et al. Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J 2013, 10.1093/eurheartj/eht046.